OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Hmmm....down again today but still hanging on in there...

Other than at Introduction to market when did OXB treble in a year leave alone in weeks. I would settle for either one.

last yr for one!

some nice big buys coming in

Rvitler

I may be missing something, but since 8/9/03 the highest price of OXB has been 28.5p.
The lowest has been 14.5p
Since 24/8/04 when it was 14.5p the trend line gives a growth rate of 7.9%

I hold shares in this company, but I find your expectations a little unrealistic.

A doubling of the price of this share over a 12month period would be exceptional and very pleasing and V. rewarding. I would be appreciative of a Price Rise to 21 over the next 8weeks. That MAYbe on the cards. IT would give be a little profit.

I also think this share falls into the group of holdings I have called Gambles. And if they are lucky and the products "cure" the conditions they are designed for and don't kill the patients in the process they may have a lucrative future. But it is a gamble with hge odds against the punter.

Fred1New, you are not very optimistic, why do you hold the shares, I am with rvilter on this co and predict 50p next yr. They have had a very up and down life with the top being 30 intra day earlier in the yr and 5p low in 2003. I bought some at 7 then and 10p yrsago, and have seen it double and halve, double and halve etc, as it'sa very spec stock, notwithstanding this I firmly believe it's one of the most promising bios and i have had a few!, and the potential is for a multi-bagger which i hope will happen next yr. If not next, then 06, and will continue to trade in the meantime no doubt. Frednew - lets not get too serious, all holders on these sites like to ramp somewhat, look at RTD. True, it's somewhat of a gamble but then so are most! but look at the knowledge and breakthrough tech OXB have and the intellectual prop value should one of their prods become big, then the sky's the limit. Don't forget also that the market sentiment is dead at the presenttime , these have been 1.32 back in the glorious bull run in 2000, and the amount of progress is really undervalued from when they came to market at 50p in 90's. 50p is not at all unreasonable, in my opinion so rvilter's hope of doubling up is not too optimistic.

Personally I agree with both the views expressed by Fred 1 and Robstuff and both arguments are valid. Recently I decided to build up a stake in 175,000 OXB shares after reading that a leading broker has put a target price on the stock of 60p within the next 18 months.

Whether or not this is going to be achieved only time will tell. There are plenty of other safer investments on the stock market but I could not resist a punt on OXB because of the huge rewards if the share price moves upwards.

In 2004 I've held shares at different times in JKX, HTG, SEY and CPL although I made profits in all of these stocks I could have made a lot more money if I had held not sold them too early. I've got a hunch OXB will deliver and will hold onto them for as a long as it takes.

Merry Xmas to all and profitable New Year!

1704 - Seems we all agree all it takes now is for OXB to do their stuff and the market to respond. I am impressed that you classify a 175,000 holding as a punt !! Merry Christmas

have stocked up with oxb at knock down price and ready for the new yr tips to propell it forward, followed by more newsflow in the early part of next yr so look forward to nice gains from here.

For those of us who are patient on this one, here some good news:

Oxford Biomedica PLC
05 January 2005


FOR IMMEDIATE RELEASE 5 JANUARY 2005


OXFORD BIOMEDICA SIGNS LENTIVECTOR(R) LICENSING AGREEMENT WITH BIOGEN IDEC

Oxford, UK: 5 January 2005 - Oxford BioMedica (LSE: OXB), the leading gene
therapy company, announced today that it has entered into an agreement to
license its LentiVector technology to Biogen Idec (NASDAQ: BIIB) for use in
research activities. Under the terms of the agreement, Oxford BioMedica will
receive an upfront licence payment and an annual maintenance fee. Further
financial details were not disclosed.

LentiVector, a lentivirus-based system, is one of the most powerful technologies
available for gene delivery to a wide range of cell and tissue types. The
technology has applications both in therapeutic products and drug discovery, as
a tool for target validation and the creation of targeted disease models. It
has also been shown to enhance the efficiency of developing transgenic birds and
mammals. Oxford BioMedica has a comprehensive portfolio of US and European
patents covering the LentiVector technology.

Oxford BioMedica's Senior Vice President Commercial Development, Peter Nolan,
said: 'We are delighted to add Biogen Idec to our list of licencees for the
LentiVector technology. This agreement is a further demonstration of the
technology's superiority and broad utility. We expect Oxford BioMedica's
LentiVector technology to become the system of choice for safe and effective
gene delivery in drug discovery and transgenics.'


For further information, please contact:

Oxford BioMedica plc: Tel: +44 (0)1865 783 000
Professor Alan Kingsman, Chief Executive

Peter Nolan, SVP Commercial Development

City/Financial Enquiries: Tel: +44 (0)20 7466 5000
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan
Communications

Scientific/Trade Press Enquiries: Tel: +44 (0)20 7886 8150
Sue Charles/ Katja Stout/ Ashley Lilly

Northbank Communications


Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.

In addition to its technical expertise in gene delivery, Oxford BioMedica has
in-house clinical, regulatory and manufacturing know-how. The development
pipeline includes two novel anti-cancer products in clinical trials; two
neurotherapy products in advanced preclinical development for Parkinson's
disease and retinopathy; and three further preclinical neurotherapy products.
The Company is underpinned by an extensive preclinical and research portfolio
and over 80 patent families, which represents one of the broadest patent estates
in the field.

The Company has established a neurotherapy pipeline of product candidates based
on its LentiVector technology, which includes ProSavin(R) for Parkinson's
disease, RetinoStat(R) for retinopathy, MoNuDin(R) for motor neuron disease,
SMN1-G for spinal muscular atrophy and Innurex(R) for nerve repair. Current
licencees of the LentiVector technology for drug discovery and transgenic
applications include Merck & Co and Viragen.


Further information is available at
http://www.oxfordbiomedica.co.uk



2. LentiVector technology

Oxford BioMedica's LentiVector gene delivery technology, based on lentiviral
vectors, is arguably the most potent system currently available for treating a
range of diseases, particularly those of the central nervous system. Oxford
BioMedica has shown that its lentiviral vectors are able to deliver genes with
high efficiency to a variety of both dividing and non-dividing cells, including
neurons in the brain.

Oxford BioMedica has three issued US patents and a European patent for its
LentiVector technology. These include broad composition of matter claims and
methods of production claims for lentiviral vector gene delivery systems of both
human and non-human origin. The patents also cover derivatives of lentiviral
vector systems that, unlike many versions of lentiviral vectors, have real
clinical utility because of their safety. The Oxford BioMedica team was the
first to construct lentiviral vectors that contain no viral genes at all, and
which comprise the minimum number of viral components in the viral particles. It
is this minimisation of the vectors that is the subject of these patents. This
work was done using vectors based on HIV and Equine Infectious Anaemia Virus
(EIAV), a horse virus that is not linked to any disease in humans.


3. Biogen Idec

Biogen Idec creates new standards of care in oncology and immunology. As a
global leader in the development, manufacturing, and commercialization of novel
therapies, Biogen Idec transforms scientific discoveries into advances in human
healthcare. For product labeling, press releases and additional information
about the company, please visit
http://www.biogenidec.com/




This information is provided by RNS
The company news service from the London Stock Exchange

Another licence agreement, more good news just the start to what should be a massive yr for oxb.

We do seem to have a persistent seller,25k 10k though the trades list doe's not reflect the true amount of buying, some of the other sells are infact buys.

rvitler, you're right. More good news but, as always, the SP does absolutely f**k all. What on earth does this one need to start it heading skywards?

And now its below where it was before the announcement on the 5th! Heaven help us if they ever get any bad news....or perhaps the SP will actually go up!

About to explode?....

or implode?....

we need some good positive trial results on this one.

positive news so it can go down you mean. COME ON!!! you b***ard thing get moving up

Love the comment AMharry4899 - I think you captured all our thoughts! Agree, so frustrating when if in the US, this co's sp would be 20 times the price.

Aaah...20x...that would pay for tonight's bottle of wine...

Someone has just acquired 3% OF THE CO and the shares still go down. If I sold some the sp would shoot up, so lets just say i've sold today.